QuantuMDx Group is a young and vibrant medical devices company developing hand-held and portable
low cost diagnostic, genomic sequencing & proteomic platforms capable of supporting the delivery of personalised medicine across both developed and developing nations.

Our focus is to develop simple, easy to use devices that not only deliver rapid & accurate - sample to result - medical diagnosis for complex diseases within minutes at the patient’s side, but can integrate with mobile apps for ongoing support and education of patients.

Our first commercial product, due out in 2013, will be the Q-POC™, QuantuMDx’s hand-held point of care platform, with first commercial assays in companion diagnostics and multi-drug resistant infectious disease testing (including TB, HIV and STIs).

Products in development include Q-SEQ™, a portable genomic sequencer, and InVenio™, a whole proteome array.

 

Quantumds Group expands The Nanomal Project, Northgene and Quantumdx Asia
Latest news from Quantumdx Group
  • QuantuMDx and Genome Institute of Singapore announce collaboration
    Read Press Release

  • Nanomal present handheld device at BioMalPar
    Read Press Release

  • QMDx rapid malaria test to combat growing
    malaria drug resistance threat

    Read Press Release

  • QMDx partners with Chemical Nanoscience Laboratories
    Read more

  • QMDx expand commercial DNA analysis portfolio
    with Northgene acquisition

    Read more